share_log

Kovo Completes Shares for Debt Transaction

Kovo Completes Shares for Debt Transaction

Kovo完成股份置换债务交易
newsfile ·  07/24 12:21

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Kovo Healthtech Corporation (TSXV: KOVO) ("Kovo" or the "Corporation") is pleased to announce that, further to its news release dated May 20, 2024, the TSX Venture Exchange (the "TSXV") has approved the Corporation's previously announced debt conversion transaction (the "Debt Conversion Transaction") and the Corporation settled outstanding debt in the aggregate amount CDN$2,257,229.56 owing to its largest secured creditor, Avonlea Ventures #2 Inc. ("AVI") by issuing 57,543,906 common shares in the capital of the Corporation ("Common Shares") at a deemed issue price per Common Share equal to $0.035 and 4,863,861 Common Shares at a deemed issue price per Common Share equal to $0.05. In aggregate, 62,407,767 Common Shares (the "Settlement Shares") were issued to AVI and are subject to a customary four month plus one day hold period.

不列颠哥伦比亚省温哥华--(Newsfile Corp.,2024年7月24日)——Kovo Healthtech Corporation(多伦多证券交易所股票代码:KOVO)(“Kovo” 或 “公司”)欣然宣布,继2024年5月20日发布的新闻稿之后,多伦多证券交易所风险交易所(“TSXV”)批准了该公司先前宣布的债务转换交易(“债务转换交易”),该公司总共结了未偿债务金额为2,257,229.56加元,这要归因于其最大的有担保债权人Avonlea Ventures #2 Inc.(“AVI”),发行了57,543,906股普通股公司资本(“普通股”),每股普通股的认定发行价格等于0.035美元,按每股普通股的认定发行价格计算为4,863,861股普通股,等于0.05美元。总共向AVI发行了62,407,767股普通股(“结算股”),按惯例持有四个月加一天。

Upon the TSXV acceptance of the Debt Conversion Transaction: (i) the forbearance agreement dated February 27, 2024 between Kovo and AVI terminated and the Corporation is no longer subject to the default interest rate provided for in the senior loan and security agreement dated as of April 20, 2023 (the "Loan Agreement"); and (ii) the amendment and restatement of the Loan Agreement (the "Amended and Restated Loan Agreement") is deemed effective and, among other things, extends the maturity date of the remaining indebtedness owed to AVI (the "Remaining Indebtedness") to April 30, 2025 and provides AVI with the right to convert the Remaining Indebtedness into Common Shares (the "Additional Conversion Right") at a fixed price of CDN$0.05 per share (the "Loan Agreement Amendments", with the Debt Conversion Transaction and the Loan Agreement Amendments collectively, the "Transaction"). As a condition to obtaining the TSXV acceptance, the Corporation and AVI filed undertakings with the TSXV confirming that: (i) Kovo has not and will not make any adjustments to the outstanding equity incentive awards issued under the Corporation's equity incentive plan as a consequence of or in respect of the Transaction; and (ii) AVI shall not exercise its Additional Conversion Right unless, after such conversion, Kovo continues to meet the applicable Continued Listing Requirements in accordance with the policies of the TSXV.

多伦多证券交易所接受债务转换交易后:(i)Kovo与AVI之间的宽容协议于2024年2月27日终止,公司不再受截至2023年4月20日的优先贷款和担保协议(“贷款协议”)中规定的违约利率的约束;(ii)贷款协议的修订和重述(“经修订和重述的贷款协议”)被视为有效,除其他外,延长了欠AVI的剩余债务(“剩余债务”)的到期日)至2025年4月30日,并赋予AVI以每股0.05加元的固定价格将剩余负债转换为普通股(“额外转换权”)的权利(“贷款协议修正案”,债务转换交易和贷款协议修正案统称为 “交易”)。作为获得多伦多证券交易所接受的条件,公司和AVI向多伦多证券交易所提交了承诺,证实:(i) Kovo过去和将来都不会对根据公司股权激励计划发放的未偿股权激励奖励进行任何调整;(ii) AVI不得行使其额外转换权,除非Kovo在转换后继续根据政策满足适用的持续上市要求多伦多证券交易所。

About Kovo HealthTech Corporation

关于 Kovo 健康科技公司

Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .

Kovo HealthTech Corporation是一家成长中的医疗保健技术公司,专门从事计费即服务,为2250多家美国医疗保健提供商提供SaaS式的经常性收入合同和软件。Kovo 帮助医疗保健提供商以数字方式无缝跟踪和管理复杂的患者护理登记、服务、账单和付款。目前,Kovo通过其客户为超过3.5万名患者处理超过2.5亿加元(合2亿美元)的年度账单交易。通过提供有效的计费方式,Kovo帮助医疗保健从业人员获得报酬,使他们能够专注于提供优质的医疗服务。要了解有关Kovo的更多信息并了解Kovo的最新新闻,请访问。

For more information:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777

欲了解更多信息:
彼得·巴克,董事会主席
investors@kovo.co
1-866-558-6777

Forward Looking Information

前瞻性信息

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Corporation's settlement of certain debt obligations owed to entities controlled by a current directors of the Corporation, the future financial condition of the Corporation and its prospects, including any proposed debt restructuring transaction, including the Debt Conversion Transaction and the Loan Agreement Amendments. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

本新闻稿包含适用证券法所指的前瞻性陈述和前瞻性信息。这些陈述与未来事件或未来表现有关。除历史事实陈述以外的所有陈述可能是前瞻性陈述或信息。更具体地说,不限于,本新闻稿包含前瞻性声明和信息,涉及公司清偿欠公司现任董事控制的实体的某些债务、公司的未来财务状况及其前景,包括任何拟议的债务重组交易,包括债务转换交易和贷款协议修正案。前瞻性陈述和信息基于公司管理层做出的某些关键预期和假设。尽管公司管理层认为此类前瞻性陈述和信息所依据的预期和假设是合理的,但不应过分依赖前瞻性陈述和信息,因为无法保证这些陈述和信息会被证明是正确的。

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Corporation's ability to continue operations without adequate capital, the Corporation's ability to raise further capital, the Corporation's ability to meet the terms of its current debt obligations and to repay its indebtedness with or without the Debt Conversion Transaction and the Loan Agreement Amendments, the likelihood of the Corporation satisfying its ongoing obligations under the proposed Debt Conversion Transaction and Loan Agreement Amendments, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties, and the likelihood of any debt restructuring transaction being consummated, and the Corporation not defaulting in the future. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

提供前瞻性陈述和信息的目的是提供有关公司当前对未来的预期和管理计划的信息。提醒读者,依赖此类陈述和信息可能不适合用于其他目的,例如做出投资决策。由于前瞻性陈述和信息涉及未来的事件和状况,因此就其本质而言,它们涉及固有的风险和不确定性。由于许多因素和风险,实际结果可能与目前的预期有重大差异。其中包括但不限于公司在没有足够资本的情况下继续运营的能力、公司筹集更多资金的能力、公司履行其当前债务义务条款和偿还债务的能力,无论是否进行债务转换交易和贷款协议修正案,公司履行其在拟议的债务转换交易和贷款协议修正案下的持续义务的可能性,公司高效成功发展的能力新的机会,未能确定未来的交易对手,任何债务重组交易完成的可能性,以及公司将来不会违约。因此,读者不应过分依赖本新闻稿中包含的前瞻性陈述和信息。请读者注意,上述因素清单并不详尽。本新闻稿中包含的前瞻性陈述和信息自发布之日起作出,除非适用的证券法有要求,否则不承诺公开更新或修改任何前瞻性陈述或信息,无论是由于新信息、未来事件还是其他原因。本警告声明明确限制了本新闻稿中包含的前瞻性陈述或信息。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发